ScoreWhy is United Therapeutics Corp. ?
1
High Management Efficiency with a high ROE of 16.12%
2
Company has a low Debt to Equity ratio (avg) at times
3
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 16.12%
4
The company has declared Positive results for the last 8 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 1,556.2 MM
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
- OPERATING PROFIT(Q) Highest at USD 411.2 MM
5
With ROE of 17.59%, it has a attractive valuation with a 4.33 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 67.51%, its profits have risen by 18% ; the PEG ratio of the company is 1.5
6
Market Beating performance in long term as well as near term
- Along with generating 67.51% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to United Therapeutics Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is United Therapeutics Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
United Therapeutics Corp.
68.56%
1.86
49.54%
S&P 500
20.78%
0.92
19.35%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
17.29%
EBIT Growth (5y)
20.70%
EBIT to Interest (avg)
31.53
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.41
Tax Ratio
22.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
32.42%
ROE (avg)
16.12%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
4.33
EV to EBIT
19.08
EV to EBITDA
18.09
EV to Capital Employed
6.80
EV to Sales
9.11
PEG Ratio
1.49
Dividend Yield
NA
ROCE (Latest)
35.63%
ROE (Latest)
17.59%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 1,556.2 MM
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
OPERATING PROFIT(Q)
Highest at USD 411.2 MM
RAW MATERIAL COST(Y)
Fallen by 1.73% (YoY
NET SALES(Q)
Highest at USD 799.5 MM
OPERATING PROFIT MARGIN(Q)
Highest at 51.43 %
NET PROFIT(Q)
Highest at USD 334.83 MM
EPS(Q)
Highest at USD 7.16
-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 2.21 times
Here's what is working for United Therapeutics Corp.
Operating Cash Flow
Highest at USD 1,556.2 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD 411.2 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Net Sales
Highest at USD 799.5 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at 51.43 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Net Profit
Highest at USD 334.83 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 7.16
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by 1.73% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 21.9 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for United Therapeutics Corp.
Inventory Turnover Ratio
Lowest at 2.21 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
